YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) + Yasminelle (SH T 00186 D)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Contraceptives, Oral
Conditions
Contraceptives, Oral
Trial Timeline
May 1, 2004 → Feb 1, 2005
NCT ID
NCT00673686About YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) + Yasminelle (SH T 00186 D)
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) + Yasminelle (SH T 00186 D) is a phase 2 stage product being developed by Bayer for Contraceptives, Oral. The current trial status is completed. This product is registered under clinical trial identifier NCT00673686. Target conditions include Contraceptives, Oral.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00673686 | Phase 2 | Completed |
Competing Products
4 competing products in Contraceptives, Oral
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD1981 + Neovletta 21/28 + Placebo AZD1981 | AstraZeneca | Phase 1 | 33 |
| Leios/Alesse | Pfizer | Pre-clinical | 22 |
| EV/DNG (Qlaira, BAY86-5027) + Progestin Only Pills | Bayer | Pre-clinical | 20 |
| Levonorgestrel Emergency Pill (BAY86-5028) + Postinor 2 | Bayer | Phase 1 | 30 |